Latest News & Features
Americas
Hector Chagoya and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril examine how Mexico applies the Budapest Treaty, which covers microorganisms in the patent process. 29 November 2018
Big Pharma
In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan of Potter Clarkson explores the lessons for patent drafting. 28 November 2018
Americas
A new facet of Mexico’s linkage system between patents and pharmaceutical drugs raises several questions that necessitate a careful approach from patent assignees and agents, as Mariana Gonzalez-Vargas of Becerril, Coca & Becerril reports. 12 November 2018
Americas
With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected. 26 October 2018
Americas
While cannabis companies in the US can’t protect their brands with federal trademark protection, there are other options for them when seeking IP rights, as LSIPR finds out. 24 October 2018
Americas
The implementation of precision medicine represents a huge, possibly unprecedented, challenge to conventional clinical practice across the breadth of healthcare disciplines, says Daniel Lim of Kirkland & Ellis. 23 October 2018
Biotechnology
An EU court ruling on gene-editing regulation has sparked widespread concerns in the scientific and legal communities, as LSIPR finds out. 22 October 2018
Americas
Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more. 19 October 2018
Big Pharma
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports. 17 October 2018
Americas
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out. 15 October 2018